-       Report 
   - March 2024
    -  106 Pages 
    Europe
   
   From       €3096EUR$3,450USD£2,717GBP 
                -       Report 
   - March 2024
    -  98 Pages 
    Middle East, Africa
   
   From       €3096EUR$3,450USD£2,717GBP 
                -       Report 
   - March 2024
    -  106 Pages 
    Asia Pacific
   
   From       €3096EUR$3,450USD£2,717GBP 
                -       Report 
   - March 2024
    -  94 Pages 
    North America
   
   From       €3096EUR$3,450USD£2,717GBP 
                -       Report 
   - March 2024
    -  92 Pages 
    
   From       €3096EUR$3,450USD£2,717GBP 
                 -       Report 
   - October 2023
    -  204 Pages 
    Global
   
   From       €3993EUR$4,450USD£3,505GBP 
                -       Report 
   - April 2023
    -  160 Pages 
    Global
   
   From       €4441EUR$4,949USD£3,898GBP 
                -       Report 
   - April 2023
    -  147 Pages 
    Global
   
   From       €4441EUR$4,949USD£3,898GBP 
                -       Report 
   - August 2024
    -  150 Pages 
    Global
   
   From       €2503EUR$2,789USD£2,196GBP 
                -       Report 
   - April 2024
    -  192 Pages 
    Global
   
   From       €4442EUR$4,950USD£3,898GBP 
                -       Report 
   - November 2023
    -  200 Pages 
    Global
   
        €4482EUR$4,995USD£3,934GBP 
                        The Selective Estrogen Receptor Modulators (SERMs) market is a subset of the Women's Health market, focusing on the use of SERMs to treat a variety of conditions related to female reproductive health. SERMs are a type of drug that can act as either an agonist or antagonist of the estrogen receptor, depending on the tissue type. This allows them to be used to treat conditions such as endometriosis, uterine fibroids, and menopausal symptoms. SERMs can also be used to reduce the risk of breast cancer    and osteoporosis.
SERMs are available in both oral and topical forms, and are often used in combination with other treatments. They are generally considered to be safe and effective, with few side effects.
Some companies in the SERMs market include Pfizer, Novartis, AstraZeneca, and Eli Lilly. Show Less   Read more